<DOC>
	<DOCNO>NCT00791258</DOCNO>
	<brief_summary>The initial 12 week portion 20 week study examine ability combination olmesartan medoxomil amlodipine low blood pressure patient high blood pressure sufficient blood pressure reduction use one anti-hypertension drug ( monotherapy ) . The final 8 week 20 week study examine ability combination olmesartan medoxomil , amlodipine hydrochlorothiazide lower blood pressure patient population . All three medication test approved FDA treatment high blood pressure , amlodipine olmesartan currently approve use combination form .</brief_summary>
	<brief_title>A Dose Escalation Study Combination Antihypertensive Drug Treatment Various Groups Patients Who Not Respond Single Drug Treatment Their High Blood Pressure</brief_title>
	<detailed_description />
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Amlodipine Besylate , Olmesartan Medoxomil Drug Combination</mesh_term>
	<criteria>&gt; = 18 year age Hypertension uncontrolled current monotherapy Females : negative serum pregnancy test screen post menopausal hysterectomy tubal ligation practice approve method birth control Pregnant females Uncontrolled hypertension multiple drug , except hydrochlorothiazide/triamterene Diabetes require insulin Serious disorder may limit ability evaluate efficacy safety treatment History myocardial infarction , bypass graft , angioplasty heart failure within past 6 month History Class III IV congestive heart failure History stroke transient ischemic attack within last 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>